DSIP 15mg

Peer-reviewed findings highlighting key biological mechanisms

Source: https://pubmed.ncbi.nlm.nih.gov/3622582/

Scientific Findings

This placebo-controlled, double-blind study administered DSIP to 14 middle-aged chronic insomniacs for seven successive nights and monitored both nighttime sleep and daytime function using polysomnography and psychological performance testing. The treatment substantially improved night sleep beginning with the first dose, with additional improvements following repeated administration. Crucially, sleep efficiency and daytime rest reached the levels of normal healthy controls by the end of the treatment period. The improvements in nighttime sleep carried over into the first post-treatment placebo night, suggesting effects that persisted beyond the period of administration. Daytime psychological performance and mental clarity were also assessed and showed improvement alongside the sleep measures.

Plain English Summary

This study found that DSIP progressively improved sleep quality in people with chronic insomnia over multiple nights of administration — not just on the night of injection. By the end of the treatment period, sleep efficiency reached the levels seen in healthy subjects. Researchers also noted improvements in daytime function and mental performance alongside the nighttime effects, making this one of the more comprehensive human studies examining DSIP's influence on the sleep-wake cycle.

Source: https://pubmed.ncbi.nlm.nih.gov/7698722/

Scientific Findings

This controlled study administered synthetic DSIP (25 nmol/kg) intravenously to healthy male subjects and evaluated its effects on ACTH secretion and arginine-vasopressin (AVP) response under both resting and stimulated conditions. The results showed a significant decrease in circulating ACTH levels following DSIP administration. Importantly, AVP secretion — triggered by both osmotic and orthostatic stimulation — was unaffected, indicating that DSIP's inhibitory action was selective to the ACTH pathway. The authors noted that DSIP is a well-characterized inhibitor of pituitary ACTH secretion.

Plain English Summary

This study found that DSIP selectively reduced stress hormone (ACTH) levels in human subjects without disrupting other hormonal responses. In research terms, this suggests DSIP may modulate the body's stress signaling system in a targeted way — dampening HPA axis activity without broadly interfering with other hormonal pathways. This selective profile is one of the reasons DSIP remains of interest in neuroendocrine research.

Source: https://pubmed.ncbi.nlm.nih.gov/3368469/

Scientific Findings

Published in the Proceedings of the National Academy of Sciences (PNAS), this study examined DSIP's role in the relationship between slow-wave sleep (SWS) and growth hormone (GH) release. Following sleep deprivation, subjects showed significant increases in both plasma GH concentrations and slow-wave sleep upon recovery — two responses that were blocked when a highly specific antiserum against DSIP was microinjected into the third cerebral ventricle. Control animals receiving normal serum maintained the expected GH and SWS increases. The researchers concluded that endogenous DSIP appears to act as a physiological signal mediating both slow-wave sleep induction and the associated sleep-dependent release of growth hormone.

Plain English Summary

This study provides mechanistic evidence that DSIP plays a functional role in the body's natural process of releasing growth hormone during deep sleep. When DSIP was neutralized, the normal surge of GH that follows sleep deprivation was blocked — suggesting DSIP is part of the biological link between slow-wave sleep and GH secretion. In research terms, this positions DSIP as a neuroendocrine signal at the intersection of sleep biology and growth hormone regulation — two of the primary pathways it is studied for today.